Accuray (ARAY)
(Delayed Data from NSDQ)
$1.94 USD
-0.09 (-4.43%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $1.94 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
C Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.94 USD
-0.09 (-4.43%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $1.94 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
C Value C Growth B Momentum B VGM
Zacks News
Accuray (ARAY), TrueNorth Unite to Aid Radiation Departments
by Zacks Equity Research
Accuray (ARAY) announces an agreement with TrueNorth to provide radiation oncology departments with third-party support designed to improve their department's capabilities.
Accuray's (ARAY) Precision TPS Gets Approved by China's NMPA
by Zacks Equity Research
Accuray (ARAY) announces the approval of the Accuray Precision Treatment Planning System by the Chinese Medical Products Administration.
Inogen (INGN) Down 0.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Accuray (ARAY) Up 2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for May 31st
by Zacks Equity Research
ASGN, ARAY and BGS have been added to the Zacks Rank #5 (Strong Sell) List on May 31, 2023.
New Strong Sell Stocks for May 24th
by Zacks Equity Research
DDD, ARAY and BNTGY have been added to the Zacks Rank #5 (Strong Sell) List on May 24, 2023.
Accuray (ARAY) Q3 Earnings Lag Estimates, Gross Margin Contracts
by Zacks Equity Research
Despite strength in radiation oncology, Accuray (ARAY) reports dismal third-quarter fiscal 2024 results.
Accuray (ARAY) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Accuray (ARAY) delivered earnings and revenue surprises of -500% and 11.75%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for These 4 Medical Device Stocks in Q1 Earnings?
by Indrajit Bandyopadhyay
Here is a sneak peek into how the four medical device stocks, COR, GKOS, ARAY and SRDX, might fare in their quarterly results slated to be release tomorrow.
Inari Medical, Inc. (NARI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inari Medical (NARI) delivered earnings and revenue surprises of -136.36% and 3.53%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Can the 4 Medical Device Stocks Hit Targets This Earnings Season?
by Debanjana Dey
Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how COR, GKOS, SRDX and ARAY are placed ahead of their earnings releases.
Atossa (ATOS) Reports Positive Results From EVANGELINE Study
by Zacks Equity Research
Atossa (ATOS) unveils positive results from its phase 2 EVANGELINE clinical study, which shows that (Z)-endoxifen can reduce the growth of ER+ breast cancer.
Accuray's (ARAY) CyberKnife Improves Prostate Cancer Treatment
by Zacks Equity Research
Accuray (ARAY) announces the latest data that supports the use of its CyberKnife System in the treatment of recurrent prostate cancer with stereotactic body radiation therapy.
Here's Why You Should Retain Accuray (ARAY) Stock for Now
by Zacks Equity Research
Accuray's (ARAY) solid product demand raises optimism about the stock.
Accuray (ARAY) Up 1.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Three Reasons to Retain Accuray (ARAY) Stock in Your Portfolio
by Zacks Equity Research
The continued solid demand for Accuray's (ARAY) products raises optimism about the stock.
Accuray (ARAY) Q2 Earnings Lag Estimates, Gross Margin Contracts
by Zacks Equity Research
Despite robust Services revenues, Accuray (ARAY) reports dismal second-quarter fiscal 2024 results.
Accuray (ARAY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Accuray (ARAY) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Unveiling Accuray (ARAY) Q2 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Accuray (ARAY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
Medical Product Stocks' Q4 Earnings Due on Jan 30: SYK & More
by Indrajit Bandyopadhyay
Fourth-quarter results of Medical Product companies are likely to reflect a year-over-year improvement in revenues. Let's see how SYK, COR and ARAY fare this time around.
Accuray's (ARAY) CyberKnife S7 to Enhance Radiation Treatment
by Zacks Equity Research
Accuray's (ARAY) latest generation CyberKnife S7 System is expected to boost the cancer treatment capabilities of the Providence Swedish Radiosurgery Center.
Strength Seen in PROCEPT BioRobotics Corporation (PRCT): Can Its 15.1% Jump Turn into More Strength?
by Zacks Equity Research
PROCEPT BioRobotics Corporation (PRCT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Here's Why You Should Retain Accuray (ARAY) Stock for Now
by Zacks Equity Research
The continued solid demand for Accuray's (ARAY) products raises optimism about the stock.
Accuray (ARAY) Launches VitalHold in Japan for Use With Radixact
by Zacks Equity Research
Accuray's (ARAY) VitalHold is likely to transform breast cancer treatment in Japan by integrating SGRT for precise radiotherapy. It may become a game-changer for patients and medical staff.
Accuray (ARAY) Q1 Earnings In-Line With Estimates, Revenues Top
by Zacks Equity Research
Accuray (ARAY) reports a solid fiscal first quarter top line on the back of robust Product revenues.